2024-07-31 14:59:08
Stocks
Technology

Cathie Wood's Recent Investment Moves

Cathie Wood, renowned for her Ark Investment Management, purchased $12 million of CrowdStrike shares amidst challenges. Despite its previous success, her flagship Ark Innovation ETF faced criticism and significant outflows.

Wood focuses on high-tech sectors like AI and blockchain, striving for returns, although recent performance has fallen short. Additionally, she sold Tesla shares and recently added stakes in Guardant Health, Oklo, and CRISPR Technologies, seeking opportunities in emerging companies with innovative products.

The Street
1. August 2024 um 17:46

Cathie Wood snags $12 million of battered cyber stock TheStreet Daily Newsletter

Finance
Technology
Cathie Wood, head of Ark Investment Management, bought $12 million of CrowdStrike shares after a software issue; her flagship Ark Innovation ETF had a 153% return in 2020 but has since underperformed the S&P 500, facing Morningstar's criticism and $2.2 billion in net outflows over the past 12 months; she invests in high-tech categories like artificial intelligence, blockchain, DNA sequencing, energy storage, and robotics, aiming for 15% annual returns which her funds have not achieved; she pur..
The Street
31. Juli 2024 um 22:45

Cathie Wood unloads $8 million of surging tech stock TheStreet Daily Newsletter

Finance
Technology
Cathie Wood's Ark Investment Management oversees the $6.4 billion Ark Innovation ETF, which has seen mixed performance, with a 153% return in 2020 but negative annualized returns over longer periods. Morningstar has criticized Ark's "forecasting talent," and the Ark Innovation ETF has suffered a $2.2 billion net outflow over 12 months. Wood recently sold $8 million worth of Tesla shares from the Ark Next Generation Internet ETF, despite predicting Tesla shares could reach $2,600 by 2029. Tesla..
Yahoo Finance
31. Juli 2024 um 13:45

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Finance
Technology
Cathie Wood's Ark Invest ETF is down 72% since 2021 peak. She added to stakes in Guardant Health, Oklo, and CRISPR Technologies. Guardant Health's Guardant360 is an approved liquid and tissue precision oncology test, while Shield is a colorectal cancer screening blood test nearing FDA approval, competing with Exact Sciences' Cologuard. Guardant Health completed 202,800 clinical or biopharmaceutical tests in 2022 at an average $2,536 price and over $1,500 gross profit per test, expecting $2 bil..
CW

Account

Waiting list for the personalized area


Welcome!

InfoBud.news

infobud.news is an AI-driven news aggregator that simplifies global news, offering customizable feeds in all languages for tailored insights into tech, finance, politics, and more. It provides precise, relevant news updates, overcoming conventional search tool limitations. Due to the diversity of news sources, it provides precise and relevant news updates, focusing entirely on the facts without influencing opinion. Read moreExpand

Your World, Tailored News: Navigate The News Jungle With AI-Powered Precision!